174 related articles for article (PubMed ID: 23942071)
1. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.
Hristodorov D; Mladenov R; Pardo A; Pham AT; Huhn M; Fischer R; Thepen T; Barth S
Br J Cancer; 2013 Sep; 109(6):1570-8. PubMed ID: 23942071
[TBL] [Abstract][Full Text] [Related]
2. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
3. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
[TBL] [Abstract][Full Text] [Related]
4. [Expression of epidermal growth factor-adenovirus E4orf4 fusion protein in tumor cells and its cytotoxicity].
Bu PL; Wang DM; Chen H; Huang BR
Ai Zheng; 2005 Jan; 24(1):33-9. PubMed ID: 15642197
[TBL] [Abstract][Full Text] [Related]
5. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T
Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033
[TBL] [Abstract][Full Text] [Related]
6. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
7. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
[TBL] [Abstract][Full Text] [Related]
8. Fusion protein of adenovirus E4orf4 and human epidermal growth factor inhibits tumor cell growth.
Zhou Y; Chen H; Ma XL; Xie HJ; Wang CL; Zhang SH; Wang X; Huang BR
Int J Cancer; 2009 Sep; 125(5):1186-92. PubMed ID: 19444920
[TBL] [Abstract][Full Text] [Related]
9. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
[TBL] [Abstract][Full Text] [Related]
10. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
11. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
12. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
Wang S; Zhou R; Sun F; Li R; Wang M; Wu M
Cancer Lett; 2017 Nov; 409():125-136. PubMed ID: 28923397
[TBL] [Abstract][Full Text] [Related]
13. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
14. Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: efficacy in an animal model of experimental colitis.
Hall FL; Kaiser A; Liu L; Chen ZH; Hu J; Nimni ME; Beart RW; Gordon EM
Int J Mol Med; 2000 Dec; 6(6):635-43. PubMed ID: 11078822
[TBL] [Abstract][Full Text] [Related]
15. Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy.
Niesler N; Arndt J; Silberreis K; Fuchs H
Protein Expr Purif; 2020 Nov; 175():105687. PubMed ID: 32681952
[TBL] [Abstract][Full Text] [Related]
16. [Design and activity analysis of chimeric epidermal growth factor fusion vaccine E5T-mSEA].
Yin Q; Jia H; Zhang Y; Liu C; Ma Q; Zhang B; Zhong H; Xu Q
Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):357-62. PubMed ID: 20518349
[TBL] [Abstract][Full Text] [Related]
17. TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.
Zhong J; Kang J; Wang X; Jiang W; Liao H; Yuan J
Med Oncol; 2015 Apr; 32(4):118. PubMed ID: 25782870
[TBL] [Abstract][Full Text] [Related]
18. Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.
Yoon JM; Han SH; Kown OB; Kim SH; Park MH; Kim BK
Life Sci; 1999; 64(16):1435-45. PubMed ID: 10321723
[TBL] [Abstract][Full Text] [Related]
19. Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy.
Sun R; Zhu Y; Feng H; Yang Z; Bian X; Gu P; Wang C; Liu Y
Cell Physiol Biochem; 2015; 35(5):1877-91. PubMed ID: 25871436
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]